A T memory stem cell (TSCM) is a type of long-lived memory T cell with the ability to reconstitute the full diversity of memory and effector T cell subpopulations as well as to maintain their own pool through self-renewal. TSCM represent an intermediate subset between naïve (Tn) and central memory (Tcm) T cells, expressing both naïve T cells markers, such as CD45RA+, CD45RO-, high levels of CD27, CD28, IL-7Rα (CD127), CD62L, and C-C chemokine receptor 7 (CCR7), as well as markers of memory T cells, such as CD95, CD122 (IL-2Rβ), CXCR3, LFA-1.[1][2][3] These cells represent a small fraction of circulating T cells, approximately 2-3%.[1] Like naïve T cells, TSCM cells are found more abundantly in lymph nodes than in the spleen or bone marrow; but in contrast to naïve T cells, TSCM cells are clonally expanded. Similarly to memory T cells, TSCM are able to rapidly proliferate and secrete pro-inflammatory cytokines (IFN-γ, IL-2, and TNF-α) in response to antigen re-exposure, but show higher proliferation potential compared with Tcm cells; their homeostatic turnover is also dependent on IL-7 and IL-15.[2]

Differentiaion

Longitudinal studies on TSCM dynamics in patients undergoing hematopoietic stem cell transplantation (HSCT) have shown that donor-derived TSCM cells were highly enriched early after HSCT, differentiated directly from Tn, and that Tn and TSCM cells (but not central memory or effector T cells) were able to reconstitute the entire heterogeneity of memory T cell subsets including TSCM cells.[4] Together with the transcriptome analysis of differentially expressed genes reflecting the relatedness of TSCM and Tn cells, these data support the existing hierarchical model of human T cell differentiation: naïve T cells (Tn) → stem cell like memory T cells (T scm) → central memory T cells (Tcm) → effector memory T cells (Tem) / effector T cells (Teff).[3]

After primary antigen exposure and elimination, antigen-specific TSCM preferentially survive among memory T cells and stably persist for a long term throughout the human lifespan.[5] Multiparametric flow cytometry and TCR sequencing studies showed that more than 30% of naïve T cells primed by antigen directly differentiate into TSCM cells.[1] Current observations allow to suggest that TSCM is a population which plays an essential role in maintaining a long-term memory in vivo.[2] Long-term studies on T cells in a cohort of patients vaccinated against yellow fever revealed that vaccine-induced CD8+ TSCM cells specific to yellow fever antigens were stably maintained for 25 years, capable of self-renewal ex vivo, and preserved surface markers and mRNA profiles closest to naïve T cells.[6] In another longitudinal study on leukaemia patients who had undergone HSCT, it was reported that genetically modified TSCM could be detected up to 14 years after infusion.[7] Complex analysis of TSCM dynamics under physiological conditions including stable isotope labeling, mathematical modeling, cross-sectional data from vaccinated individuals, and telomere length analysis revealed that there are at least 2 distinct TSCM subpopulations with different longevity and turnover rates: 1) short-lived, with an average half-life of 5 months, 2) long-lived, with a high degree of self-renewal and the half-life of approximately 9 years, which is consistent with the long-term maintenance of the recall response to antigen (8–15 years).[2]

Analysis of TCR β repertoire of TSCM and Tm revealed that TSCM have higher TCRβ diversity compared with Tm, that TCR sequences of TSCM were antigen-experienced and their composition differed with those of naïve T cells. It also revealed that in type I diabetes patients there was an enrichment of self-reactive clonotypes in TSCM rather than in Tm, suggesting that TSCM might serve as a pool of autoreactive T cells.[8]

In host defense

Pathogen-specific TSCM cells have been identified in a number of studies of human acute and chronic infections caused by viruses, bacteria and parasites. The presence of TSCM might be essential for the control of persisting infections, in which effector T cells undergo exhaustion and need to be restored; this was supported by the evidence of a negative correlation between the severity of chronic viral (HIV-1) and parasitic (trypanosome) infections and the frequency of circulated TSCM cells.[1]

TSCM in cancer

TSCM are considered as a promising approach in immune cell therapy in cancers due to their high proliferation capacity, longevity and increased survival as well as more potent antitumor effects compared with Tcm and Tem in vivo. Studies on adoptive cell therapy in mouse melanoma model revealed a significant linear correlation between the differentiation status of infused T cells and the strength of tumor regression in the order TSCM >TCM > TEM; TSCM infusion led to a more sustained reduction in tumor growth and correlated with a significant increase in overall survival of treated mice. Previous works on humans and mice also demonstrated that less differentiated T cells show greater proliferative capacity and ability to persist after cell transfer compared with their more differentiated counterparts; in humans, the ability of infused T cells to persist has been positively correlated with response to adoptive cell therapy.[3][9]

However, the clinical exploitation of TSCM cells is impeded due to their paucity in the peripheral blood and due to the current lack of unified protocols for generating and maintaining TSCM in vitro for clinical manufacturing. Among current efficient strategies, there is a combination of IL-7 and IL-15, which have been successfully used to generate tumor-redirected TSCM cells from naive cell precursors, with yielding cells having a gene signature of naturally occurring TSCM cells and enhanced proliferative capacity compared to other T cell subsets. This strategy can be particularly suitable for generating virus-specific TSCM cells for adoptive cell therapy to prevent or treat viral infections after transplantation or in other immunocompromised patients. Another strategy promoting the efficient generation of tumor-reactive TSCM cells relies on the activation of naïve-like T cells in the presence of IL-7, IL-21 and TWS119, which is an agonist of Wnt-β signaling. It has been found that CAR-modified TSCM cells generated this way are phenotypically, functionally and transcriptomically equivalent to naturally occurring TSCM cells; moreover, they had metabolic features which are specific for long-lived memory T cells, such as high spare respiratory capacity and low glycolytic metabolism (predominance of oxidative phosphorylation). Such CAR-modified T cells can be redirected efficiently against required tumor antigens, and have been shown to generate durable anti-tumor responses.[1]

One of the hardest challenges in application of T cell therapies in treatment of solid tumors is the problem of CD8+ T cells exhaustion resulting from their repeated exposure to tumor antigens and immunosuppressive tumor microenvironment sending inhibitory signals through the cytokines and cell surface receptors. Exhausted T cells are characterized by the expression of large amounts of inhibitory molecules such as PD-1, CTLA-4, LAG3, Tim-3, CD244/2B4, CD160, and TIGIT; they do not respond to TCR stimulation and have reduced capacity to secrete anti-tumor cytokines such as IFN-γ and TNF-α.[10] On a transcriptional level, recent studies have found that transcription factors which play key role in T cells exhaustion include TCF-1, T-bet, Eomes, PRDM1, NFAT, NR4A, IRF4 and BATF. According to the current differentiation model of T cells exhaustion, T cells stepwise lose their “stemness” while acquiring “exhaustion”.  Therefore, approaches that would avoid T cells exhaustion and would “reinvigorate” exhausted T cells have a potential to significantly improve the efficacy of cancer immunotherapies.[3]

Studies of the recent years revealed that TCF-1+ T cells, which represent early memory T cells including TSCM cells, play important roles in T cells persistence and efficacy in cancer immunotherapy. Flow cytometry analysis of tumor-infiltrating antigen-presenting cell (APC) populations in human kidney, prostate and bladder tumors revealed a significant correlation between the presence of dendritic cells (but not macrophages) and the number of TCF1+ stem-like CD8+ T cells in the tumor.[11] Subsequent immunofluorescence staining showed that TCF1+ stem-like T cells were found only in regions with high density of MHC II+ cells; in contrast, the TCF1- population of terminally exhausted CD8+ T cells was distributed across the tissue with no preference for APC dense zones. Expanded analysis of large sections of tumor tissues confirmed that tumors had many regions with dense APC zones, and TCF-1+ stem-like CD8 cells preferentially resided there. These data suggest that regions highly enriched with APC serve as an intratumoral niche for stem-like CD8+ T cells, which give rise to terminally differentiated T cells and thus sustain the anti-tumor immune response.  Furthermore, immunofluorescence analysis of large regions of tumor tissue from 26 patients with kidney cancer revealed that patients with controlled disease had significantly more MHC-II dense regions where TCF1+ CD8 T cells resided; further stratification of patients showed that patients with low MHC-II+ cell density in such regions experienced significantly impaired progression-free survival. A focused study of patients with stage III kidney cancer, around 50% of whom progress after surgery, revealed that there were >10-fold fewer immune niches in patients who progressed.[11]

Despite some variations depending on tumor type and therapy, most studies agree that tumor-infiltrating lymphocytes (TIL) in patients responding to checkpoint-blockade therapy, such as anti-PD1 therapy, contain more TCF1+ early memory T cells, while fewer T cells with exhausted phenotype compared with TILs in non-responders. A study performed on the preclinical model of colon cancer has shown that PD-1 blockade induced a shift from naïve-like to memory precursor-like subsets, which are maintained by the transcriptional regulator TCF-1. The effectiveness of CAR-T cell therapy in chronic lymphocytic leukemia has also been reported to depend on the number of early memory T cells and T cell exhaustion.[10]

References

  1. 1 2 3 4 5 Gattinoni L, Speiser DE, Lichterfeld M, Bonini C (January 2017). "T memory stem cells in health and disease". Nature Medicine. 23 (1): 18–27. doi:10.1038/nm.4241. PMC 6354775. PMID 28060797.
  2. 1 2 3 4 Costa Del Amo P, Lahoz-Beneytez J, Boelen L, Ahmed R, Miners KL, Zhang Y, et al. (June 2018). Bhandoola A (ed.). "Human TSCM cell dynamics in vivo are compatible with long-lived immunological memory and stemness". PLOS Biology. 16 (6): e2005523. doi:10.1371/journal.pbio.2005523. PMC 6033534. PMID 29933397.
  3. 1 2 3 4 Wang F, Cheng F, Zheng F (August 2022). "Stem cell like memory T cells: A new paradigm in cancer immunotherapy". Clinical Immunology. 241: 109078. doi:10.1016/j.clim.2022.109078. PMID 35840054. S2CID 250582405.
  4. ↑ Cieri N, Oliveira G, Greco R, Forcato M, Taccioli C, Cianciotti B, et al. (April 2015). "Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation". Blood. 125 (18): 2865–2874. doi:10.1182/blood-2014-11-608539. hdl:11380/1074873. PMID 25736310. S2CID 23354137.
  5. ↑ Gao S, Liang X, Wang H, Bao B, Zhang K, Zhu Y, Shao Q (March 2021). "Stem cell-like memory T cells: A perspective from the dark side". Cellular Immunology. 361: 104273. doi:10.1016/j.cellimm.2020.104273. PMID 33422699. S2CID 231577763.
  6. ↑ Fuertes Marraco SA, Soneson C, Cagnon L, Gannon PO, Allard M, Abed Maillard S, et al. (April 2015). "Long-lasting stem cell-like memory CD8+ T cells with a naïve-like profile upon yellow fever vaccination". Science Translational Medicine. 7 (282): 282ra48. doi:10.1126/scitranslmed.aaa3700. PMID 25855494. S2CID 21394251.
  7. ↑ Oliveira G, Ruggiero E, Stanghellini MT, Cieri N, D'Agostino M, Fronza R, et al. (December 2015). "Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory". Science Translational Medicine. 7 (317): 317ra198. doi:10.1126/scitranslmed.aac8265. PMID 26659572. S2CID 7668541.
  8. ↑ Wang S, Wang L, Liu Y, Zhu Y, Liu Y (2021-08-25). "Characteristics of T-cell receptor repertoire of stem cell-like memory CD4+ T cells". PeerJ. 9: e11987. doi:10.7717/peerj.11987. PMC 8401816. PMID 34527440.
  9. ↑ Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, et al. (August 2011). "Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice". Clinical Cancer Research. 17 (16): 5343–5352. doi:10.1158/1078-0432.CCR-11-0503. PMC 3176721. PMID 21737507.
  10. 1 2 Ando M, Ito M, Srirat T, Kondo T, Yoshimura A (March 2020). "Memory T cell, exhaustion, and tumor immunity". Immunological Medicine. 43 (1): 1–9. doi:10.1080/25785826.2019.1698261. PMID 31822213. S2CID 209317256.
  11. 1 2 Jansen CS, Prokhnevska N, Master VA, Sanda MG, Carlisle JW, Bilen MA, et al. (December 2019). "An intra-tumoral niche maintains and differentiates stem-like CD8 T cells". Nature. 576 (7787): 465–470. Bibcode:2019Natur.576..465J. doi:10.1038/s41586-019-1836-5. PMC 7108171. PMID 31827286.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.